Trial Profile
An Open-Label Clinical Trial Evaluating the Safety and Pharmacodynamics of Sirolimus and Panitumumab in Subjects With Advanced Non-Small Cell Lung Cancer
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 12 Sep 2018
Price :
$35
*
At a glance
- Drugs Panitumumab (Primary) ; Sirolimus (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Amgen
- 04 Jun 2009 New trial record.